Document Detail


Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants.
MedLine Citation:
PMID:  2863804     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The rate of retrolental fibroplasia in relation to prenatal and neonatal characteristics was explored on the basis of a cohort of 3,025 neonates with birth weight less than 1,750 g. The overall rate of retrolental fibroplasia of any degree at hospital discharge was 11%, varying from 43% for those with birth weight between 500 and 749 g to 3% for those in the 1,500- to 1,750-g category. Among the potential determinants, the main interest was in nonhyperoxic characteristics, conditional on measures of prematurity and oxygen supplementation. Maternal diabetes and antihistamine use during the last 2 weeks of pregnancy were associated with significantly higher rates of retrolental fibroplasia, whereas toxemia was associated with lower rates. Frequent apneic spells, bronchopulmonary dysplasia, and sepsis in the neonate were also associated with significantly higher rates. On the other hand, the data indicate no independent role of low Apgar score, intraventricular hemorrhage, exchange transfusion, patent ductus arteriosus, or certain other characteristics previously postulated as risk factors.
Authors:
D M Purohit; R C Ellison; S Zierler; O S Miettinen; A S Nadas
Related Documents :
2804184 - Prostaglandin stability in human milk and infant gastric fluid.
9236384 - Transaxillary minithoracotomy for modified blalock-taussig shunt.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Pediatrics     Volume:  76     ISSN:  0031-4005     ISO Abbreviation:  Pediatrics     Publication Date:  1985 Sep 
Date Detail:
Created Date:  1985-10-07     Completed Date:  1985-10-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  339-44     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / complications
Apnea / complications
Birth Weight
Bronchopulmonary Dysplasia / complications
Female
Histamine H1 Antagonists / adverse effects
Humans
Infant, Low Birth Weight
Infant, Newborn
Infant, Premature, Diseases / epidemiology*,  etiology
Infection / complications
Pre-Eclampsia / complications
Pregnancy
Pregnancy Complications, Hematologic
Pregnancy in Diabetics / complications
Retinopathy of Prematurity / epidemiology*,  etiology
Risk
United States
Grant Support
ID/Acronym/Agency:
HL23121/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Histamine H1 Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current concepts in the management of common urologic problems in infants and children.
Next Document:  The significance of thyroid-stimulating antibody (TSAb) in the management and prognostic evaluation ...